Medipattern's B-CAD MRI'TM' Named Technology Innovation of the Year by Frost & Sullivan.

TORONTO -- Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), a leading developer of computer-aided detection (CAD) software applications for medical imaging, is pleased to announce that its CAD for MRI (B-CAD MRI(TM)) has won the 2006 Medical Imaging Technology Innovation of the Year Award, presented by the analyst team of Frost & Sullivan, a leading global provider of industry analysis and research. The Award is presented to the company that has demonstrated technological superiority within its industry, and recognizes the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.

Frost & Sullivan made the award on the basis of the technology innovation of Medipattern's B-CAD MRI in contrast to competitors, its ability to compare features in both MRI and ultrasound, and particularly noted both Medipattern's crossing of the modality barrier from ultrasound to MRI, and its focus on identification and analysis of morphological features of lesions in breast images. On the basis of its research, Frost & Sullivan expects the unique technology to be quickly and widely adopted by a wide range of end-users, from hospitals to diagnostic imaging centres.

Frost & Sullivan also noted that Medipattern's B-CAD MRI complies with American College of Radiology (ACR) BI-RADS(R) guidelines for ultrasound and MRI procedures in breast imaging. The research team at Frost & Sullivan indicated that Medipattern's B-CAD MRI is, to date, the only CAD for MRI to use both kinetics -- where the wash-in, wash-out time of contrast agent is used to predict whether tissue is cancerous -- and morphology -- where gross and acute analysis of physical characteristics has high positive and negative predictive value. According to Frost & Sullivan, radiologists suggest that MRI CAD software that can combine both kinetic and morphological analysis holds the potential to significantly reduce or avoid the need for biopsy, while detecting subtle tissue changes that occur pre-metastasis.

Non-invasive, Medipattern's technology also has the potential to markedly improve patient experience. The Company will seek FDA approval for the software, with general market availability expected in the Fall of 2006.

"This broadly recognized award gives Medipattern powerful industry validation of the approach we have been taking with our CAD platform, Cadenza(TM)," said Jeff Collins, President and CEO of Medipattern. "Frost & Sullivan recognized not only Medipattern's B-CAD MRI, but the strength and flexibility of our overall platform, and the ability to navigate between both ultrasound and MRI data within the same software application. Frost & Sullivan's Innovation Award is its highest honor and highlights the industry's belief in the strategic direction Medipattern has chosen."

"B-CAD MRI has the potential to revolutionize the breast imaging industry by offering a highly sensitive and accurate diagnostic software package that benefits both the patient and the physician," said Subha Basu, healthcare research analyst for Frost & Sullivan. "I can expect this technology to be eagerly implemented by end-users in hospitals and diagnostic imaging centres."

The Medipattern Corporation develops computer-aided detection (CAD) software applications for medical imaging. These applications enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical application is B-CAD(TM) for breast ultrasound. B-CAD uses pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in ultrasound images of the breast. For additional information, please visit the Company's website at: www.medipattern.com.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

B-CAD(TM) and B-CAD MRI(TM) are trademarks of The Medipattern Corporation. Medipattern(R) is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's financial performance, operations or business environment. Such statements are based on Medipattern's operations, estimates, forecasts, and projections, but are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. These factors include those set forth in the company's corporate filings, (posted at www.sedar.com). Consequently, readers should not rely on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. Although any forward-looking statements are based upon what management believes to be reasonable assumptions, Medipattern cannot be certain that actual results will be consistent with these forward-looking statements, and the company disclaims any intention or obligation to update or revise any forward-looking statements for any reason.

The TSX Venture Exchange does not accept responsibility for the ad equacy or accuracy of this release and has neither approved nor disapp roved of the contents of this release.

The Medipattern Corporation (TSX VENTURE:MKI)